GlassScriptPhysician profile
Thara Abu-Mallouh
NPI 1790455095
$3,107.75
in general payments reported to CMS, 2019-2025
19 companies · $585 in 2025
The $585 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $354 · 2022: $694 · 2023: $873 · 2024: $602 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,017 · Entertainment: $43.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,016.66 |
| Entertainment | $43.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $617.03 | 2022-2025 | Durysta, Lumigan, Vuity |
| Sun Pharmaceutical Industries INC. | $473.76 | 2022-2025 | Cequa, Xelpros |
| Tarsus Pharmaceuticals, INC. | $278.40 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $266.43 | 2022-2023 | |
| Bausch & Lomb Americas INC. | $232.15 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Oyster Point Pharma, INC. | $194.19 | 2022-2025 | Tyrvaya |
| Allergan, INC. | $188.94 | 2021-2022 | |
| Dompe US, INC. | $166.03 | 2021-2024 | Oxervate |
| Aerie Pharmaceuticals, INC. | $114.70 | 2021 | |
| Alcon Vision LLC | $99.16 | 2023-2025 | Tryptyr, Eysuvis |
| Kala Pharmaceuticals, INC. | $98.45 | 2021-2022 | |
| Harrow Eye, LLC | $90.58 | 2024-2025 | Vevye |
| Coopervision INC. | $62.63 | 2023 | Misight Contact Lens |
| Novartis Pharmaceuticals Corporation | $53.32 | 2022-2023 | |
| Rxsight INC | $44.37 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $43.48 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Horizon Therapeutics Plc | $38.73 | 2023 | Tepezza |
| Eyevance Pharmaceuticals LLC | $26.11 | 2022 | |
| Ocular Therapeutix, INC. | $19.29 | 2023 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thara Abu-Mallouh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.